PT  - JOURNAL ARTICLE
AU  - Sant’Anna, Fernando Hayashi
AU  - Muterle Varela, Ana Paula
AU  - Prichula, Janira
AU  - Comerlato, Juliana
AU  - Comerlato, Carolina Baldisserotto
AU  - Roglio, Vinicius Serafini
AU  - Mendes Pereira, Gerson Fernando
AU  - Moreno, Flávia
AU  - Seixas, Adriana
AU  - Márcia Wendland, Eliana
TI  - Emergence of the novel SARS-CoV-2 lineage P.4.1 and massive spread of P.2 in South Brazil
AID  - 10.1101/2021.04.14.21255429
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.14.21255429
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255429.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255429.full
AB  - South Brazil has been the novel epicenter of Coronavirus Disease 2019 (COVID-19) in 2021, accounting for the greatest number of cumulative cases and deaths (per 100 thousand inhabitants in a week) worldwide. In this study, we analyzed 340 whole genomes of SARS-CoV-2, which were sampled between April and November 2020 in 33 cities in South Brazil. We demonstrated the circulation of two novel emergent lineages, described here as P.4 and P.4.1 (provisionally termed VUI-NP13L), and seven lineages that had already been assigned (B.1.1.33, B.1.1.28, P.2, B.1.91, B.1.1.94, B.1.195 and B.1.212). P.2 and P.4.1 demonstrated massive spread from approximately September/October 2020. Constant and consistent genomic surveillance is crucial to identify newly emerging SARS-CoV-2 lineages in Brazil and to guide decision making in the Brazilian Public Healthcare System.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Brazilian Ministry of Health along with Moinhos de Vento Hospital, through the Program for Supporting the Institutional Development of Public Health System (PROADI-SUS), financed the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Moinhos de Vento Hospital under protocol number 32149620.9.0000.5330.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in GISAID repository.